Direxion Daily Biotech Top 5 Bull 2X ETF(TBXU)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TBXU Direxion Daily Biotech Top 5 Bull 2X ETF

交易中 08-20 15:14:18 EDT

44.02

-0.76

-1.70%

最高44.02	最低43.98	成交量2,117
今开43.98	昨收44.78	日振幅0.09%
总市值330.16万	流通市值330.16万	总股本7.50万
成交额9.31万	换手率2.82%	流通股本7.50万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TBXU","market":"US","secType":"STK","nameCN":"Direxion Daily Biotech Top 5 Bull 2X ETF","latestPrice":44.0201,"timestamp":1787253020322,"preClose":44.7799,"halted":0,"volume":2117,"delay":0,"changeRate":-0.016967434049651706,"floatShares":75001,"shares":75001,"eps":0,"marketStatus":"交易中","change":-0.7598,"latestTime":"08-20 15:14:18 EDT","open":43.98,"high":44.0201,"low":43.98,"amount":93055.347378,"amplitude":0.000895,"askPrice":43.63,"askSize":300,"bidPrice":43.58,"bidSize":300,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787256000000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":44.7799,"sharesOutstanding":100001,"nav":41.6,"aum":3120021.31,"dividendRate":0.014125,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":44.7799,"preClose":44.7799,"latestTime":"19:15 EDT","volume":208,"amount":9431.6192,"timestamp":1787181339982,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.186242},"requestUrl":"/m/hq/s/TBXU/wiki","defaultTab":"wiki","newsList":[{"id":"2660472972","title":"港股早评：三大指数高开逾1.1%，生物科技股、黄金股大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2660472972","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660472972?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:37","pubTimestamp":1787189821,"startTime":"0","endTime":"0","summary":"美股止住三连跌，日韩股市大幅反弹。港股三大指数集体高开，恒指涨1.11%，国指涨1.27%，恒生科技指数涨1.69%。大型科网股全线上涨，京东涨近3%，美团、阿里巴巴涨2%，腾讯、小米、百度皆上涨；mRNA肿瘤疫苗三期大获成功，全产业链迎来价值重估，生物医药股大涨，康希诺生物、云顶新耀大涨15%，金斯瑞生物科技大涨13%，金价大涨，黄金股领衔有色金属股上涨，另外，消费电子股、海运股、煤炭股部分走低。(格隆汇)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260820/32340660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["KCAI","GLDW","BK4585","TBXU","159562","VXUS","BIOY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660476170","title":"AI生物科技股Twist Bioscience涨超22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660476170","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660476170?lang=zh_cn&edition=full","pubTime":"2026-08-20 06:26","pubTimestamp":1787178401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["AGIX","VTHR","CHAT","TBXU","AIPO","ARTY","QTOC","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105025052","title":"再生元制药旗下Pasatru获欧洲药品管理局审评，全球申报在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1105025052","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105025052?lang=zh_cn&edition=full","pubTime":"2026-08-20 02:00","pubTimestamp":1787162410,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其研发的药物Pasatru已被欧洲药品管理局纳入审评流程。与此同时，该公司正积极筹备在全球范围内提交该药物的上市申请。欧洲药品管理局的审评启动，为这款药物在欧洲地区的获批前景增添了重要砝码。业界分析认为，Pasatru若能顺利通过审评，有望为相关疾病领域带来新的治疗选择。再生元制药在创新药物研发领域深耕多年，此次针对Pasatru的全球布局，也彰显了其对这一候选药物商业潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","IBBQ","LU1974910355.USD","LU0320765992.SGD","REGN","TBXU","LU2362541513.USD","LU0889565916.HKD","LU2023250504.SGD","LU2237438978.USD","LU2468319806.SGD","LU1917777945.USD","BK4588","BK4585","LU0823434583.USD","LU0882574055.USD","LU2106854487.HKD","LU2089984988.USD","LU0289739699.SGD","LU0053666078.USD","LU2362540622.SGD","LU0823416689.USD","LU0823434740.USD","LU0058720904.USD","LU2362541273.HKD","LU0114720955.EUR","IBB","BK4139","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188134905","title":"再生元制药获FDA批准：Pasatru（Garetosmab-Grts）上市，治疗成人进行性骨化性纤维发育不良","url":"https://stock-news.laohu8.com/highlight/detail?id=1188134905","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188134905?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:59","pubTimestamp":1787162353,"startTime":"0","endTime":"0","summary":"再生元制药公司今日宣布，其研发的新药Pasatru已获得美国食品药品监督管理局的正式批准，用于治疗成人进行性骨化性纤维发育不良。这一罕见疾病此前一直缺乏有效的治疗手段，此次获批为患者带来了新的希望。FDA的此次批准基于多项临床研究数据，结果显示Pasatru在减缓异位骨化进展方面表现出显著疗效，且安全性可控。未来，再生元制药计划进一步拓展Pasatru的适应症范围，并探索其在其他相关疾病中的潜在应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU2362541513.USD","LU0109394709.USD","LU2362541273.HKD","LU1917777945.USD","LU2362540622.SGD","BK4585","IBBQ","BK4588","LU0320765992.SGD","LU0882574055.USD","LU1974910355.USD","LU2106854487.HKD","LU0889565916.HKD","LU2237438978.USD","LU0289739699.SGD","LU0823434740.USD","LU2089984988.USD","REGN","LU0058720904.USD","LU0823434583.USD","BK4139","LU2468319806.SGD","BBH","LU2023250504.SGD","IBB","TBXU","LU0114720955.EUR","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660447273","title":"受利好消息提振，美股生物科技股普涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2660447273","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660447273?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:21","pubTimestamp":1787138473,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BIOY","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660585446","title":"瑞穗上调安进目标价至352美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660585446","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660585446?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:55","pubTimestamp":1787129710,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0889565916.HKD","LU1571399168.USD","SG9999001440.SGD","IBB","IE0002141913.USD","BK4566","LU1023059063.AUD","BK4588","LU0320765992.SGD","LU0868494617.USD","LU1061106388.HKD","BK4139","PBE","IE00B2B36J28.USD","LU0289739699.SGD","BK4533","LU0058720904.USD","UUP","BK4581","IBBQ","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1057294990.SGD","BK4585","IE0009355771.USD","TBXU","BK4534","LU1983299246.USD","LU2242652126.USD","IE00BJT1NW94.SGD","UDN","LU2242646821.SGD","LU0122379950.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","LU2112291526.USD","AMGN","PJP","BBH","BIB","BK4599","LU2468319806.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192416297","title":"TScan Therapeutics披露：安进将终止与其研究合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1192416297","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192416297?lang=zh_cn&edition=full","pubTime":"2026-08-19 05:04","pubTimestamp":1787087050,"startTime":"0","endTime":"0","summary":"值得注意的是，安进作为全球领先的生物制药公司，此举无疑将对TScan Therapeutics的研发管线及未来战略布局产生深远影响。TScan Therapeutics方面表示，将仔细评估这一变化对公司在研项目及整体运营带来的潜在影响。对于TScan Therapeutics而言，此番变故或许意味着需要重新校准其研发路径，并探索新的合作机会或资金来源以继续推进其创新疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","IE0009355771.USD","IBB","BBH","BK4534","IE00BFTCPJ56.SGD","LU0289739699.SGD","IE00BJJMRZ35.SGD","BK4588","LU2112291526.USD","LU2468319806.SGD","LU0889565916.HKD","IE00BJT1NW94.SGD","BIB","IE00B4R5TH58.HKD","LU1057294990.SGD","BK4599","PJP","LU0122379950.USD","SG9999001440.SGD","BK4566","LU0109394709.USD","TCRX","IE00B2B36J28.USD","IBBQ","LU0058720904.USD","LU1023059063.AUD","LU1061106388.HKD","LU0320765992.SGD","BK4581","BK4585","LU2242652126.USD","LU2242646821.SGD","BK4533","AMGN","LU0868494617.USD","TBXU","LU1571399168.USD","PBE","BK4539","LU1983299246.USD","IE0002141913.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660304824","title":"深圳易慕峰生物科技股份有限公司向港交所提交IPO申请，华泰金融控股（香港）为保荐人兼整体协调人。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660304824","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660304824?lang=zh_cn&edition=full","pubTime":"2026-08-18 07:26","pubTimestamp":1787009193,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["TBXU","IPOS","BK4127","REDS","BIOY","FRHC","KCE","159940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137019504","title":"美股开盘 | 三大指数涨跌不一，闪迪涨超3%，Argenx SE涨近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137019504","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137019504?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:32","pubTimestamp":1786973544,"startTime":"0","endTime":"0","summary":"8月17日，美股三大指数开盘涨跌不一，道琼斯指数跌0.23%，标普500指数涨0.04%，纳斯达克综合指数涨0.24%。美股存储股普涨，SK海力士、西部数据、闪迪涨超3%，美光科技、希捷科技涨超2%。OmniAb涨超23%，公司此前宣布与礼来达成3.7亿美元药物研发协议。Argenx SE涨近9%，Efgartigimod治疗肌炎III期试验成功。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836757.USD","FTXH","LU2491050154.USD","WUGI","SPY","LU2108987350.USD","LU0234572021.USD","FHLC","BK4581","BOBP","FTXL","LU0354030511.USD","IE00B19Z3581.USD","LU0079474960.USD","PPH","LU1093756168.USD","LU0354030438.USD","LU0353189680.USD","DOG","CNEQ","IETC","LU1057294990.SGD","LU1823568750.SGD","IE0004445239.USD","SKHY","LU2112291526.USD","COWG","LU2089984988.USD","IE00B5949003.HKD","LU2361044865.SGD","LU2111349929.HKD","BK4527","LU2458330243.SGD","LU2417539215.USD","GDOC","LU1061106388.HKD","SKHYV","SG9999001424.SGD","OZEM","LU2168563687.JPY","MHIP","LU0082616367.USD","LU2461242641.AUD","SK","JGRO","STX","BK4505","LU0316494557.USD","LU2471134523.USD","AIQ","LU0385154629.USD","SKHU","LU2750360641.GBP","LU1064131342.USD","LU1551013342.USD","PTF","LU2265009873.SGD","LU0882574055.USD","LU1712237335.SGD","LU1323610961.USD","BK4553","LU2324357040.USD","IHE","LU0444971666.USD","IE00BJJMRX11.SGD","LU1069347547.HKD","IE0002141913.USD","LU2237443978.SGD","LU2237443382.USD","LU0859254822.USD","MU","MMAX","LU0238689110.USD","LU0787776722.HKD","SHOC","SNDK","TBXU","LU1316542783.SGD","LU2023250504.SGD","LU0006306889.USD","BK4007","BK4532","LU1720051108.HKD","VHT","ILDR","LU1989764664.SGD","LU2063271972.USD","BK4512","LU2491050071.SGD","LU1642822529.SGD","LU0106261372.USD","SKHX","SG9999015952.SGD","IYH","LU2602419157.SGD","LU1868836591.USD","LU0353189763.USD","IE00BJJMRZ35.SGD","QQQG","CGGO","XLV","LU0345770993.USD","PJP","SNDC","IE00BFSS8Q28.SGD","LU2462591350.SGD","LU0203202063.USD","SKUU","LU2750360997.AUD","UDOW","IE0009356076.USD","IE00B7KXQ091.USD","IE00B1BXHZ80.USD","LU0158827781.USD","SGXZ81514606.USD","LU2237443622.USD","FMED","IE000M9KFDE8.USD","LU0289739699.SGD","LU1069344957.HKD","SMH","LU0158827948.USD","LU0683600562.USD","SOXX","DIA","STX.AU","LU0792757196.USD","LU2458330169.SGD","LU1720051017.SGD","LU0203347892.USD","LU2746668974.SGD","IE00B4JS1V06.HKD","WLDR","IE00BKPKM429.USD","LU1280957306.USD","LU2211815571.USD","IE00B7SZLL34.SGD","MUU","LU0786609619.USD","LU2102340556.USD","TMED","SG9999018857.SGD","SPXS","WDCX","FTEC","CHPX","LU0417517546.SGD","IE0001KFT4U8.USD","LU1127390331.HKD","LU0274383776.USD","DXD","SPYM","IE00B19Z9Z06.USD","LLY","HYNX","LU2237443549.SGD","LU2360106947.USD","SKHA","SG9999014880.SGD","DRMY","LU0708995401.HKD","MEDI","VOO","IE00B894F039.SGD","AIFD","LU1235294995.USD","LU0889565916.HKD","IE00BFSS7M15.SGD","CNAV","LU0225283273.USD","LU2168564495.EUR","LU2456880835.USD","UPRO","LU1804176565.USD","SG9999013999.USD","LU1023059063.AUD","DDM","ELIS","LU2236285917.USD","LU1145028129.USD","LU0323591593.USD","CANC","IE00BWXC8680.SGD","IE0002270589.USD","LU1974910355.USD","BK4575","SNXX","LU0476273544.USD","LLYX","LU2250418816.HKD","LU2357627491.SGD","LU0432979614.USD","HRTS","IE00B775H168.HKD","LU2028103732.USD","SKDD","IE00BN29S564.USD","LU0203345920.USD","LU0823434583.USD","LU2264538146.SGD","LU1989764748.USD","LU0266013472.USD","DISK","LU0642271901.SGD","MIC","LU2462157665.USD","IE00B19Z3B42.SGD","IE00BK4W5M84.HKD","SCHA","IE0034235188.USD","LU1093756325.SGD","BK4170","LLII","SPUU","IE00BFTCPJ56.SGD","LU1670628061.USD","LU2237438978.USD","IE00BSNM7G36.USD","SNDQ","SPYU","LU2168564222.USD","TMSL","CHPS","RULE","CHAT","LU0154236417.USD","LU2471134952.CNY","LU2491049909.HKD","IBB","LU2552382215.SGD","LU2361045086.USD","BK4139","THNR","LU1670627923.USD","SOXQ","LEGR","SG9999001176.SGD","SNDG","LU0094547139.USD","LU0964807845.USD","LU0466842654.USD","SG9999015945.SGD","LU2756315318.SGD","LU0889566641.SGD","YSPY","IXN","WDC","SGXZ99366536.SGD","LU0823434740.USD","LU0133085943.USD","07709","BK4599","LU2360107168.USD","IE0004445015.USD","TRUH","CURE","LU2290526834.HKD","LU2087625088.SGD","SG9999014914.USD","BK4566","IXJ","DMAX","LU0320765992.SGD","WDNA","IE00B2B36J28.USD","LU2403377893.USD","LU0820562030.AUD","LU0444973449.USD","SGXZ57979304.SGD","TRFK","FXL","BK4141","LU0456855351.SGD","SPYQ","LU0072461881.USD","FSMD","EFIV","LU1623119135.USD","SG9999014906.USD","LU2106854487.HKD","SDS","LU1803068979.SGD","LU1366333091.USD","LU1983299246.USD","IE00B4R5TH58.HKD","MULL","LU1366192091.USD","XNTK","SG9999017495.SGD",".IXIC","HBMX","HIBL","LU1629891620.HKD","SDOW","LU1979441026.SGD","LU2286300806.USD","LU1291159041.SGD","IE00BKDWB100.SGD","LU0640476718.USD","LU1868836914.USD","LU0256863811.USD","LU0240878834.USD","LU2023250330.USD","LU1868837300.USD","LU2361044949.HKD","SSO","LU2048586759.USD","LU2089284900.SGD","BK4554","LU0689472784.USD","LU2471134879.HKD","SH","SPXL","LU2357305700.SGD","IE0009355771.USD","LU2931357623.SGD","LU1983260115.SGD","LU1035773651.USD","SG9999014898.SGD","EMSF","YMmain","LU0056508442.USD","LU0210536198.USD","LU0162691827.USD","LU0471298777.SGD","LU2271345857.HKD","IE0005OL40V9.USD","LU0471298694.HKD","LU2054465674.USD","SG9999015978.USD","LU0157215616.USD","LU1035775433.USD","JDOC","FAI","LU1267930730.SGD",".SPX","PSI","AGNG","BK4579","LU0345770308.USD","SKHZ","LU2746668461.USD","LU2023251221.USD",".DJI","LU1868837136.USD","LU2552382058.USD","OPTZ","LU0109391861.USD","AIS","LU2089283258.USD","LU0943347566.SGD","BK4585","LU2168564065.EUR","BK4588","LU0719512351.SGD","LU0672654240.SGD","XLK","IE00BK4W5L77.USD","BK4543","LU0006061336.USD","LU0203201768.USD","LU1548497426.USD","LU0109392836.USD","LU2237443895.HKD","ARTY","LU0058720904.USD","IE00B19Z9P08.USD","LU2360106780.USD","USXF","SCHM","SGXZ51526630.SGD","LU2552382132.HKD","LU0963586101.USD","FDTX","LU1551013425.SGD","IE00BJJMRY28.SGD","LU0889565833.HKD","LU2237443465.HKD","LU0127658192.USD","SG9999015986.USD","LU1917777945.USD","LU2213496289.HKD","LU1815336760.USD","IVV","FCUS","LU0320765059.SGD","IE00B1XK9C88.USD","LU0114720955.EUR","BK4534","LU2089985449.USD","LU2756315664.SGD","SG9999018865.SGD","SG9999001176.USD","LU1232071149.USD","LU0882574139.USD","LU1046421795.USD","SGXZ31699556.SGD","SPYH","LU0820561909.HKD","LU0256863902.USD","LU1814569148.SGD","LU0174119429.USD","LU0109394709.USD","QQQA","MUYY","IE0034235303.USD","LU0823416689.USD","LU0096364046.USD","LU0054578231.USD","BK4533","LU1674673428.USD","LU2168564149.EUR","LU1914381329.SGD","SMU00main","BK4605","MEDX","SNDU","TTXU","RXL","LU0061475181.USD","VGT","LU0957808578.USD","LU0122379950.USD","LU1267930813.SGD","SPXU","LU1989771016.USD","GB00BDT5M118.USD","LU0097036916.USD","LU1778281490.HKD","EGGY","SMAX","LU0820561818.USD","LU0198837287.USD","LU1861215975.USD","BAI","LU0240877869.USD","MUD","ARGX","LU1674673691.USD","LU1852331112.SGD","LU0081259029.USD","LU2896262040.SGD","LU2543165471.USD","LU1861220033.SGD","LU2468319806.SGD","LU2471134796.USD","MUZ","SPDN","ELIL","BK7142","LU1988902786.USD","LLYZ","IE00BJT1NW94.SGD","IE00BJLML261.HKD","BK4516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481020","title":"美股异动 | Argenx(ARGX.US)盘前涨超10% 自身免疫性肌炎药物Vyvgart III期研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660481020?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:48","pubTimestamp":1786963699,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4134","BK4139","BK4505","IBB","LU0889565916.HKD","LU0109394709.USD","IE0009355771.USD","IE0034235188.USD","IE00BFTCPJ56.SGD","III","TBXU","IE0002141913.USD","FMED","IE00B2B36J28.USD","LU1983260115.SGD","LU0320765992.SGD","LU0823416689.USD","BK4585","ARGX","LU2324357040.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848605","title":"美股异动丨Argenx SE盘前大涨超7%，Efgartigimod治疗肌炎III期试验成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848605","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660848605?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:37","pubTimestamp":1786959424,"startTime":"0","endTime":"0","summary":"Argenx SE(ARGX.US)盘前涨超7%，报913.38美元。消息面上，公司宣布，Efgartigimod在治疗自身免疫性肌炎的III期ALKIVIA试验中达到了主要终点。在52周时，与安慰剂相比，药物在总改善评分(TIS) 上实现了具有统计学和临床意义的改善。此次试验成功对Argenx意义重大，开辟新市场：自身免疫性肌炎在美国影响约10万人，其中IMNM约2万，DM约4万，这是一个尚未被满足的巨大医疗市场。公司计划为IMNM提交加速审批申请，并将与FDA讨论DM的申报可能性。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32337291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IE00BJT1NW94.SGD","IE00B2B36J28.USD","TBXU","IBB","LU0823416689.USD","IE0002141913.USD","LU2324357040.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","BK4588","III","ARGX","LU1983260115.SGD","BK4139","BK4505","IE0009355771.USD","LU0109394709.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4585","LU0889565916.HKD","IE0034235188.USD","FMED","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660648687","title":"步长制药：控股子公司药品临床试验申请获受理，研发投入约3175.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660648687","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660648687?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:16","pubTimestamp":1786958196,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NVOH","NVOX","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660853994","title":"argenx SE（ARGX）宣布Efgartigimod治疗自身免疫性肌炎的3期ALKIVIA试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2660853994","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660853994?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:43","pubTimestamp":1786956188,"startTime":"0","endTime":"0","summary":"该试验评估了皮下注射药物VYVGART Hytrulo在成人自身免疫性肌炎中的疗效，包括免疫介导的坏死性肌病和皮肌炎。在IMNM亚组分析中，治疗组同样展现出14.8分的显著改善。这是全球首个在没有任何批准疗法的IMNM领域取得统计学显著与临床意义改善的三期临床试验。自身免疫性肌炎属于罕见且高度致残的疾病，长久以来临床严重依赖大剂量激素和广谱免疫抑制剂。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303846","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983260115.SGD","IE0009355771.USD","LU0889565916.HKD","BK4505","FMED","BK4588","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","LU0823416689.USD","IBB","LU0320765992.SGD","IE00B2B36J28.USD","TBXU","IE0034235188.USD","ARGX","BK4139","IE0002141913.USD","LU2324357040.USD","BK4585","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660101358","title":"巴克莱上调安进目标价至380美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660101358","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660101358?lang=zh_cn&edition=full","pubTime":"2026-08-17 11:05","pubTimestamp":1786935953,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2242652126.USD","LU1983299246.USD","PJP","IE0009355771.USD","LU2468319806.SGD","LU2089984988.USD","LU0320765992.SGD","BK4588","AMGN","IBB","TBXU","UUP","LU2242646821.SGD","LU0868494617.USD","PBE","BK4534","LU0058720904.USD","IBBQ","LU0109394709.USD","BK4581","BK4599","IE00BJJMRZ35.SGD","UDN","LU0889565916.HKD","LU1061106388.HKD","IE00BJT1NW94.SGD","BK4533","LU1571399168.USD","LU2112291526.USD","IE0002141913.USD","BIB","LU0289739699.SGD","LU1023059063.AUD","IE00B2B36J28.USD","BK4139","LU1057294990.SGD","SG9999001440.SGD","BBH","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0122379950.USD","BK4585","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658196566","title":"百济神州（06160）盘初涨3.94% 与安进联合开发及商业化的安泰适正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658196566","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658196566?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:39","pubTimestamp":1786412383,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 盘初上涨3.94%，最新报221.60港元，成交额1.86亿港元。消息面上，百济神州8月11日早上宣布，由百济神州与安进公司共同负责在中国开发和商业化的安泰适正式投入临床使用。此外，8月10日，百济神州宣布与Revolution Medicines达成一项多方面合作协议。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987884","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","LU2242646821.SGD","BK1161","BBH","BK1500","SG9999001440.SGD","LU2242652126.USD","BK4533","LU1969619763.USD","BK1583","LU1061106388.HKD","LU1983299246.USD","IE0002141913.USD","BK4566","BK4534","LU1770034418.SGD","LU0228659784.USD","LU2089984988.USD","IBBQ","LU0307460666.USD","LU0828237510.HKD","BK4599","688235","LU0588546209.SGD","LU0289739699.SGD","LU1571399168.USD","BK1588","IE00B4R5TH58.HKD","06160","LU2468319806.SGD","IE00B2B36J28.USD","BK4139","ONC","LU1023059063.AUD","IE00BJT1NW94.SGD","LU1057294990.SGD","KURE","LU0122379950.USD","IE0009355771.USD","BK4526","IBB","PJP","BK4585","PBE","LU0109394709.USD","BIB","BK4588","LU2112291526.USD","AMGN","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658930620","title":"美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658930620","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658930620?lang=zh_cn&edition=full","pubTime":"2026-08-10 23:39","pubTimestamp":1786376356,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1069344957.HKD","LU2089984988.USD","IE00B19Z9Z06.USD","IBBQ","LU0058720904.USD","LU1585245621.USD","LU1674673428.USD","LU2462157665.USD","PBE","BK4588","BK4567","IE0009355771.USD","BBH","IE00B19Z9P08.USD","IBB","LU1093756168.USD","LU2417539215.USD","SGXZ57979304.SGD","IDNA","LU0417517546.SGD","LU2362541513.USD","BK4585","LU2456880835.USD","BIB","LU1674673691.USD","IE00BZ9MQY76.HKD","LU0256863811.USD","LU1035775433.USD","SG9999001176.SGD","LU0289739699.SGD","IBBJ","BK4139","LU1430594728.SGD","LU2362540622.SGD","VRTX","LU0889565916.HKD","IE0002141913.USD","SG9999001176.USD","LU0234570918.USD","IE00B19Z3581.USD","LU2324357040.USD","SG9999013999.USD","LU2236285917.USD","LU1778281490.HKD","GNMX","IE0002270589.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","TBXU","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658793062","title":"美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658793062","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658793062?lang=zh_cn&edition=full","pubTime":"2026-08-10 23:39","pubTimestamp":1786376356,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，$福泰制药(VRTX)$(VRTX.US)早盘涨近7%，创历史新高;而竞争对手$Sionna Therapeutics(SION)$(SION.US)暴跌超90%，创记录新低。消息面上，SION表示，由于SION-719实验性囊性纤维化药物在中期临床试验中未能达到主要目标，公司将终止该药物的研发。投资者此前一直担忧SION可能对VRTX的核心囊性纤维化业务构成威胁，但此次试验失败消除了这一担忧。VRTX公司销售的Trikafta和Alyftrek用于治疗囊性纤维化——这是一种罕见、慢性且会缩短寿命的遗传性疾病，会导致肺部进行性损伤。","market":"us","thumbnail":"https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478244.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0417517546.SGD","LU0079474960.USD","BK4139","LU0234570918.USD","BK4567","IE00B2B36J28.USD","LU2456880835.USD","LU1093756168.USD","LU2462157665.USD","IE0002141913.USD","LU0256863811.USD","LU1430594728.SGD","IE00B19Z9Z06.USD","IE00BJJMRZ35.SGD","LU2236285917.USD","IE00B894F039.SGD","LU1778281490.HKD","SG9999001176.USD","GNMX","LU0109394709.USD","LU1674673428.USD","LU1585245621.USD","LU2362541273.HKD","IE00B19Z3581.USD","IBBJ","IE00BJT1NW94.SGD","LU0058720904.USD","SG9999001176.SGD","IE00B19Z9P08.USD","LU2468319806.SGD","BK4532","LU0320765992.SGD","LU1674673691.USD","IE00B19Z3B42.SGD","IDNA","VRTX","SG9999013999.USD","IE00BZ9MQY76.HKD","BIB","IBBQ","LU2417539215.USD","IE00BFTCPJ56.SGD","SGXZ57979304.SGD","LU0061475181.USD","IE00B4R5TH58.HKD","TBXU","BBH","PBE","IBB","LU2362541513.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118060249","title":"再生元加拿大公司宣布Libtayo获加拿大卫生部批准用于特定类型癌症辅助治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1118060249","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118060249?lang=zh_cn&edition=full","pubTime":"2026-08-06 23:49","pubTimestamp":1786031342,"startTime":"0","endTime":"0","summary":"（路透社消息）再生元加拿大公司（Regeneron Canada）近日宣布，其免疫药物Libtayo已获得加拿大卫生部（Health Canada）的批准，可用于高风险皮肤鳞状细胞癌（cutaneous squamous cell carcinoma）的辅助治疗。这一批准标志着该药物在癌症治疗领域迈出了重要一步，为高风险患者群体带来了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","TBXU","LU0889565916.HKD","BBH","LU2237438978.USD","IBBQ","LU0320765992.SGD","LU2023250504.SGD","LU1917777945.USD","LU0882574055.USD","IBB","LU0823416689.USD","BK4585","LU0114720955.EUR","BK4139","REGN","LU2089984988.USD","LU2362540622.SGD","LU0289739699.SGD","LU0053666078.USD","LU0058720904.USD","LU2362541273.HKD","LU2468319806.SGD","BK4588","LU0109394709.USD","LU2362541513.USD","LU0823434740.USD","LU1974910355.USD","LU0823434583.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101250335","title":"再生元加拿大公司：Libtayo获加拿大卫生部批准用于高危皮肤鳞状细胞癌的辅助治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1101250335","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101250335?lang=zh_cn&edition=full","pubTime":"2026-08-06 23:31","pubTimestamp":1786030270,"startTime":"0","endTime":"0","summary":"再生元加拿大公司宣布，其药物Libtayo已获得加拿大卫生部的批准，用于高危皮肤鳞状细胞癌的辅助治疗。这一关键进展为高风险患者提供了新的治疗选择，填补了该领域未满足的医疗需求。Libtayo作为免疫疗法，通过激活人体免疫系统来对抗肿瘤，其安全性和有效性已在临床试验中得到验证。加拿大卫生部的批准基于对复发风险的显著降低数据，标志着再生元在肿瘤治疗领域的持续扩展。此次获批，不仅巩固了Libtayo在皮肤癌治疗中的地位，也为患者带来了更早干预的机会，有望改善预后并降低复发率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU2468319806.SGD","LU0114720955.EUR","LU0823434583.USD","LU0320765992.SGD","LU0109394709.USD","LU2362541273.HKD","IBB","BK4585","LU2362540622.SGD","TBXU","LU0823434740.USD","LU0823416689.USD","BK4139","REGN","BK4588","LU0058720904.USD","LU2362541513.USD","LU1974910355.USD","LU2023250504.SGD","BBH","LU0882574055.USD","LU0053666078.USD","LU2106854487.HKD","LU2089984988.USD","LU0889565916.HKD","IBBQ","LU1917777945.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632843","title":"毕马威：并购交易恢复活力 年内或迎来分拆浪潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632843","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657632843?lang=zh_cn&edition=full","pubTime":"2026-08-06 21:18","pubTimestamp":1786022287,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XLFI","TBXU","ACTV","RFG","FFSM","IEFN","MNA","UYG","CANC","PEVC","MMID","PBPH","RSPH","IYH","BK4585","VXF","DFMC","IBBQ","GTPE","BK4588","PRVT","PSP","AAUM","TMED"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.1684},{"period":"1month","weight":0.3529},{"period":"3month","weight":0.554},{"period":"6month","weight":0.2323},{"period":"1year","weight":0.6647},{"period":"ytd","weight":0.4415}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0363},{"period":"3month","weight":0.0355},{"period":"6month","weight":0.1155},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"exchange":"ARCA","name":"Direxion Daily Biotech Top 5 Bull 2X ETF","nameEN":"Direxion Daily Biotech Top 5 Bull 2X ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Direxion Daily Biotech Top 5 Bull 2X ETF(TBXU)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Direxion Daily Biotech Top 5 Bull 2X ETF(TBXU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Direxion Daily Biotech Top 5 Bull 2X ETF,TBXU,Direxion Daily Biotech Top 5 Bull 2X ETF股票,Direxion Daily Biotech Top 5 Bull 2X ETF股票老虎,Direxion Daily Biotech Top 5 Bull 2X ETF股票老虎国际,Direxion Daily Biotech Top 5 Bull 2X ETF行情,Direxion Daily Biotech Top 5 Bull 2X ETF股票行情,Direxion Daily Biotech Top 5 Bull 2X ETF股价,Direxion Daily Biotech Top 5 Bull 2X ETF股市,Direxion Daily Biotech Top 5 Bull 2X ETF股票价格,Direxion Daily Biotech Top 5 Bull 2X ETF股票交易,Direxion Daily Biotech Top 5 Bull 2X ETF股票购买,Direxion Daily Biotech Top 5 Bull 2X ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Direxion Daily Biotech Top 5 Bull 2X ETF(TBXU)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Direxion Daily Biotech Top 5 Bull 2X ETF(TBXU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}